Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
0.00% $1.680
America/New_York / 7 mai 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 8.06 mill |
EPS: | -10.20 |
P/E: | -0.160 |
Earnings Date: | May 14, 2024 |
SharesOutstanding: | 4.80 mill |
Avg Daily Volume: | 2.18 mill |
RATING 2024-05-07 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.160 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.03x |
Company: PE -0.160 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-1.068 (-163.56%) $-2.75 |
Date: 2024-05-07 |
Expected Trading Range (DAY) |
---|
$ 0.864 - 2.50 ( +/- 48.57%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-02 | Locklear Lisa | Sell | 410 | Class A Common Stock |
2024-05-02 | Agafonova Nataliya | Sell | 308 | Class A Common Stock |
2024-04-11 | Hare Joshua | Buy | 42 553 | Class A Common Stock |
2024-04-10 | Hare Joshua | Buy | 106 383 | Class A Common Stock |
2024-04-10 | Hare Joshua | Buy | 106 383 | Warrant (right to buy) |
INSIDER POWER |
---|
39.62 |
Last 100 transactions |
Buy: 1 179 927 | Sell: 677 468 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.680 (0.00% ) |
Volume | 0.349 mill |
Avg. Vol. | 2.18 mill |
% of Avg. Vol | 16.01 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.